Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J in $4 Billion Settlement Talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2013 | 11:16pm CET

Johnson & Johnson (JNJ) has agreed to pay $4 billion to settle more than 7,500 lawsuits over the company's recalled hip-implant products, Bloomberg News reported Tuesday, citing three people familiar with the agreement.

The settlement will be announced next week, Bloomberg reported.

Full story at: www.bloomberg.com/news/2013-11-12/j-j-said-to-reach-4-billion-deal-to-settle-hip- awsuits.html

Write to nymonitoring@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 JOHNSON & JOHNSON : The Woodrow Wilson Center (WWC) - Discussion
12/02 HIP DAMAGES : Jury tells J&J to pay another $1 billion
12/02 JOHNSON & JOHNSON : to pay $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : J&J ordered to pay record $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : Dallas Jury Returns $1 Billion-Plus Verdict in Defective DeP..
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/29 WPP : Acquires US Company Promotion Execution Partners
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
More news
Sector news : Pharmaceuticals - NEC
12/02 Pharma execs weigh in on possible changes under Trump
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
12/01 GLAXOSMITHKLINE : GSK biotech asthma drug wins UK approval after extra price cut
12/01 PERRIGO : Cohen's SAC Capital in $135 million settlement with Elan investors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/02 J&J Actelion bid reportedly tops $250/share
12/02 GILEAD : M&A Coming Soon
12/02 WALL STREET BREAKFAST : Non-Farm Payrolls In Focus
12/01 Johnson & Johnson hit with $1B-plus jury verdict on faulty hip implants
12/01 With 2016 Nearing A Close, Our Dividend Growth Portfolio Is Up Almost 10%
Advertisement
Financials ($)
Sales 2016 72 061 M
EBIT 2016 22 017 M
Net income 2016 16 371 M
Finance 2016 18 064 M
Yield 2016 2,80%
P/E ratio 2016 18,94
P/E ratio 2017 16,70
EV / Sales 2016 3,98x
EV / Sales 2017 3,70x
Capitalization 304 591 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
More Results